172 related articles for article (PubMed ID: 31069135)
1. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.
Jahan N; Talat H; Alonso A; Saha D; Curry WT
Oncoimmunology; 2019; 8(5):e1577108. PubMed ID: 31069135
[TBL] [Abstract][Full Text] [Related]
2. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
3. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
4. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
5. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
6. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
7. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
[TBL] [Abstract][Full Text] [Related]
8. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
9. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
10. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
11. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
12. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
13. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
14. Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.
Dejaegher J; Verschuere T; Vercalsteren E; Boon L; Cremer J; Sciot R; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2017 Nov; 141(9):1891-1900. PubMed ID: 28681455
[TBL] [Abstract][Full Text] [Related]
15. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
16. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Patel MA; Kim JE; Theodros D; Tam A; Velarde E; Kochel CM; Francica B; Nirschl TR; Ghasemzadeh A; Mathios D; Harris-Bookman S; Jackson CC; Jackson C; Ye X; Tran PT; Tyler B; Coric V; Selby M; Brem H; Drake CG; Pardoll DM; Lim M
J Immunother Cancer; 2016; 4():28. PubMed ID: 27190629
[TBL] [Abstract][Full Text] [Related]
17. The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma.
Zhou Z; Lin L; An Y; Zhan M; Chen Y; Cai M; Zhu X; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():529-543. PubMed ID: 34136421
[TBL] [Abstract][Full Text] [Related]
18. Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.
Garbow JR; Johanns TM; Ge X; Engelbach JA; Yuan L; Dahiya S; Tsien CI; Gao F; Rich KM; Ackerman JJH
Front Oncol; 2021; 11():693146. PubMed ID: 34249742
[TBL] [Abstract][Full Text] [Related]
19. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.
Kjaergaard J; Wang LX; Kuriyama H; Shu S; Plautz GE
J Neurosurg; 2005 Jul; 103(1):156-64. PubMed ID: 16121986
[TBL] [Abstract][Full Text] [Related]
20. Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Han MG; Wee CW; Kang MH; Kim MJ; Jeon SH; Kim IA
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
